Cantor Fitzgerald Initiates Coverage On AgomAb Therapeutics with Overweight Rating
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiation
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating.
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating.